Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015 Jul;119:89-96. doi: 10.1016/j.antiviral.2015.01.004

Wang CC, Hsu CS, Liu CJ et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol. 2008 May;23(5):779-82

Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf). 2015 Aug 13. pii: gov040

Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011 Sep;26(9):1361-7

Olubamwo OO, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis - a systematic review. Clin Physiol Funct Imaging. 2015 Jan 26. doi: 10.1111/cpf.12229

Jou JH, Muir AJ. In the clinic. Hepatitis C. Ann Intern Med. 2012 Dec 4;157(11):ITC6-1 – ITC6-16

Nyalakonda H, Utay NS. A new era of therapy for hepatitis C virus infection. Curr Opin Infect Dis. 2015 Oct;28(5):471-478

Kudo M. Tailor-Made Therapy for viral hepatitis: Recent advances. Digestion 2011;84(suppl 1):1-4

Liu Q, Bengmark S, Qu S. Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis. BMC Gastroenterol. 2010 May 20;10:49

Abd El-Kader SM, Al-Jiffri OH, Al-Shreef FM et al. Liver enzymes and psychological well-being response to aerobic exercise training in patients with chronic hepatitis C. Afr Health Sci. 2014 Jun;14(2):414-9

Huisman EJ, van Meer S, van Hoek B et al. Effects of preventive versus "on-demand" nutritional support on paid labour productivity, physical exercise and performance status during PEG-interferon-containing treatment for hepatitis C. Clin Res Hepatol Gastroenterol. 2015 Jul 15. pii: S2210-7401(15)00140-0

Pattullo V, Duarte-Rojo A, Soliman W et al. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. Liver Int. 2013 Mar;33(3):410-9

Payen JL, Pillard F, Mascarell V et al. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy? Gastroenterol Clin Biol. 2009 Jan;33(1 Pt 1):8-14

Thomas CH, Lok ASF, Locarnini SA (Ed.) Viral hepatitis (2014) Wiley Blackwell, 4th Ed.

Freire TO, Boulhosa RS, Oliveira LP et al. n-3 polyunsaturated fatty acid supplementation reduces insulin resistance in hepatitis C virus infected patients: a randomised controlled trial. J Hum Nutr Diet. 2015 Jul 27. doi: 10.1111/jhn.12327

Himoto T, Yoneyama H, Kurokohchi K et al. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. Nutr Res. 2011 Nov;31(11):829-35

Modi AA, Feld JJ, Park Y et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010 Jan;51(1):201-9

Khalaf N, White D, Kanwal F1 et al. Coffee and caffeine are associated with decreased risk of advanced hepatic fibrosis among patients with hepatitis C. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1521-1531.e3

Cardin R, Piciocchi M, Martines D et al. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 2013 Jun;45(6):499-504

Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011 Nov;31(10):1432-48

Takagi H, Kakizaki S, Sohara N, Sato K et al. Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis. Int J Vitam Nutr Res. 2003 Nov;73(6):411-5

Farias MS, Budni P, Ribeiro CM et al. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Gastroenterol Hepatol. 2012 Jun-Jul;35(6):386-94

Groenbaek K, Friis H, Hansen M et al. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol. 2006 Sep;18(9):985-9

Melhem A, Stern M, Shibolet O et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol. 2005 Sep;39(8):737-42

Beloqui O, Prieto J, Suárez M et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res. 1993 Aug;13(4):279-82

Grant PR, Black A, Garcia N et al. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol. 2000 Aug;61(4):439-42

Neri S, Ierna D, Antoci S et al. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med. 2000 Sep;42(3):187-92

Lin CC, Yin MC. et al. Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin. Clin Nutr. 2009 Feb;28(1):34-8

Lin CC, Liu WH, Wang ZH, Yin MC. Vitamins B status and antioxidative defense in patients with chronic hepatitis B or hepatitis C virus infection. Eur J Nutr. 2011 Oct;50(7):499-506

Rocco A1, Compare D, Coccoli P et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut. 2013 May;62(5):766-73

Malaguarnera M, Vacante M, Bertino G et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J Interferon Cytokine Res. 2011 Sep;31(9):653-9

Malaguarnera G, Pennisi M, Gagliano C et al. Acetyl-L-carnitine supplementation during HCV therapy with pegylated interferon-α 2b plus ribavirin: effect on work performance; a randomized clinical trial. Hepat Mon. 2014 May 5;14(5):e11608

Romano M, Vacante M, Cristaldi E et al. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci. 2008 Apr;53(4):1114-21

Malaguarnera M, Vacante M, Giordano M et al. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol. 2011 Oct 21;17(39):4414-20

Tarao K, Fujiyama S, Ohkawa S et al. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):164-9

Niederau C, Strohmeyer G, Heintges T et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group. Hepatogastroenterology. 1998 May-Jun;45(21):797-804

Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:84-9

Berkson BM. Alpha Lipoic Acid and Liver Disease. Townsend Lett. 2007 dec. http://www.townsendletter.com/Dec2007/alphalipo1207.htm

Ridruejo E, Castiglioni T, Silva MO. Thioctic acid-induced acute cholestatic hepatitis. Ann Pharmacother. 2011 Jul;45(7-8):e43

Mendes PR, Félix Ddos S, Silva PC et al. Effect of alpha lipoic acid on the blood cell count and iron kinetics in hypertensive patients. Nutr Hosp. 2014 Nov 3;31(2):883-9

Nagamine T, Takagi H, Takayama H et al. Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Elem Res. 2000 Summer;75(1-3):53-63

Takagi H, Nagamine T, Abe T, Takayama H et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 2001 Sep;8(5):367-71

Matsuoka S, Matsumura H, Nakamura H et al. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr. 2009 Nov;45(3):292-303

Matsumura H, Nirei K, Nakamura H et al. Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C. J Clin Biochem Nutr. 2012 Nov;51(3):178-84

Abbasinazari M, Alavian SM, Behnava B et al. Effect of zinc supplementation on viral response in patients with chronic hepatitis C and Beta thalassemia major, a pilot study. J Clin Diagn Res. 2014 Dec;8(12):HC16-9

Steinbrenner H, Al-Quraishy S, Dkhil MA, Wunderlich F, Sies H. Dietary selenium in adjuvant therapy of viral and bacterial infections. Adv Nutr. 2015 Jan 15;6(1):73-82

Carreño V. Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy. Aliment Pharmacol Ther. 2014 Jan;39(2):148-62

Kato J, Miyanishi K, Kobune M et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol. 2007 Oct;42(10):830-6

Bares JM, Berger J, Nelson JE et al. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol. 2008 Sep;42(8):937-44

Yang Z, Zhuang L, Lu Y et al. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:941085

Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005 Nov;12(6):559-67

Yang Z, Zhuang L, Lu Y et al. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:941085

Biermer M, Schlosser B, Fülöp B et al. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Viral Hepat. 2012 Aug;19(8):547-53

Braun DL, Rauch A, Aouri M, Durisch N et al. A lead-in with silibinin prior to triple-therapy translates into favorable treatment outcomes in difficult-to-treat HIV/hepatitis C coinfected patients. PLoS One. 2015 Jul 15;10(7):e0133028

Braun DL, Rauch A, Durisch N et al. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. HIV Med. 2014 Nov;15(10):625-30

Wei F, Liu SK, Liu XY et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis. 2013 May;32(5):657-69

Ikeda K, Arase Y, Kobayashi M et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci. 2006 Mar;51(3):603-9

Fujioka T, Kondou T, Fukuhara A et al. Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepatol Res. 2003 May;26(1):10-14

Stern E. Two cases of hepatitis C treated with herbs and supplements. J Altern Complement Med. 1997 Spring;3(1):77-82

Kainuma M, Hayashi J, Sakai S et al. The efficacy of herbal medicine (kampo) in reducing the adverse effects of IFN-beta in chronic hepatitis C. Am J Chin Med. 2002;30(2-3):355-67

Deng G, Kurtz RC, Vickers A et al. A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. J Ethnopharmacol. 2011 Jun 14;136(1):83-7

Barakat EM, El Wakeel LM, Hagag RS. Effects of Nigella sativa on outcome of hepatitis C in Egypt. World J Gastroenterol. 2013 Apr 28;19(16):2529-36

Shikov AN, Djachuk GI, Sergeev DV et al. Birch bark extract as therapy for chronic hepatitis C--a pilot study. Phytomedicine. 2011 Jul 15;18(10):807-10

Azocar J, Diaz A. Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World J Gastroenterol. 2013 Feb 21;19(7):1085-90

Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol. 2012 Apr 12;12:32

Huber R, Müller M, Naumann J et al. Artichoke leave extract for chronic hepatitis C - a pilot study. Phytomedicine. 2009 Sep;16(9):801-4

Hampton T. Grapefruit compound battles hepatitis C. JAMA. 2008 Apr 2;299(13):1532

Morcos PN, Brennan B, Smith PF. A grapefruit a day for patients infected with hepatitis C? Hepatology. 2008 Jun;47(6):2141-2; author reply 2142-3

Halegoua-De Marzio D, Kraft WK et al. Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract. Clin Ther. 2012 Dec;34(12):2279-2285.e1

Calland N, Dubuisson J, Rouillé Y et al. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses. 2012 Oct 17;4(10):2197-217

Nakamura M, Saito H, Ikeda M et al. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J Gastroenterol. 2010 Jan 14;16(2):184-92

Mazzanti G, Di Sotto A, Vitalone A. Hepatotoxicity of green tea: an update. Arch Toxicol. 2015 Aug;89(8):1175-91

Whitsett M, Marzio DH, Rossi S. SlimQuick™-associated hepatotoxicity resulting in fulminant liver failure and orthotopic liver transplantation. ACG Case Rep J. 2014 Jul 8;1(4):220-2